Aldosterone blockade in post-acute myocardial infarction heart failure

Bertram Pitt; Roberto Ferrari; Mihai Gheorghiade; Dirk J. van Veldhuisen; Henry Krum; John McMurray; Jose Lopez-Sendon

Aldosterone blockade in post-acute myocardial infarction heart failure

Bertram Pitt^*, Roberto Ferrari, Mihai Gheorghiade, Dirk J. van Veldhuisen, Henry Krum, John McMurray, Jose Lopez-Sendon

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

7 Citations (Scopus)

Abstract

Development of heart failure (HF) or left ventricular systolic dysfunction (LVSD) significantly increases mortality post acute myocardial infarction (AMI). Aldosterone contributes to the development and progression of HF post AMI, and major guidelines now recommend aldosterone blockade in this setting. However, lack of practical experience with aldosterone blockade may make clinicians hesitant to use these therapies. This review is based on a consensus cardiology conference that occurred in May 2005 (New York City) concerning these topics. Potential barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in-hospital pharmacologic management of AMI with LVSD and/or HF is presented.

Original language	English
Pages (from-to)	434-438
Number of pages	5
Journal	Clinical Cardiology
Volume	29
Issue number	10
Publication status	Published - Oct-2006

Keywords

aldosterone
myocardial infarction
heart failure
left ventricular systolic dysfunction
eplerenone
EPHESUS
LEFT-VENTRICULAR DYSFUNCTION
SYSTOLIC DYSFUNCTION
RECEPTOR BLOCKADE
ANGIOTENSIN-II
EPLERENONE
ADULT
RAT
SPIRONOLACTONE
MANAGEMENT
MORTALITY

Handle.net

Persistent link

Cite this

@article{6bffc0306aac4507a7a66d69bf4f06ba,

title = "Aldosterone blockade in post-acute myocardial infarction heart failure",

abstract = "Development of heart failure (HF) or left ventricular systolic dysfunction (LVSD) significantly increases mortality post acute myocardial infarction (AMI). Aldosterone contributes to the development and progression of HF post AMI, and major guidelines now recommend aldosterone blockade in this setting. However, lack of practical experience with aldosterone blockade may make clinicians hesitant to use these therapies. This review is based on a consensus cardiology conference that occurred in May 2005 (New York City) concerning these topics. Potential barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in-hospital pharmacologic management of AMI with LVSD and/or HF is presented.",

keywords = "aldosterone, myocardial infarction, heart failure, left ventricular systolic dysfunction, eplerenone, EPHESUS, LEFT-VENTRICULAR DYSFUNCTION, SYSTOLIC DYSFUNCTION, RECEPTOR BLOCKADE, ANGIOTENSIN-II, EPLERENONE, ADULT, RAT, SPIRONOLACTONE, MANAGEMENT, MORTALITY",

author = "Bertram Pitt and Roberto Ferrari and Mihai Gheorghiade and {van Veldhuisen}, {Dirk J.} and Henry Krum and John McMurray and Jose Lopez-Sendon",

note = "0 Review J",

year = "2006",

month = oct,

language = "English",

volume = "29",

pages = "434--438",

journal = "Clinical Cardiology",

issn = "0160-9289",

publisher = "Wiley",

number = "10",

}

TY - JOUR

T1 - Aldosterone blockade in post-acute myocardial infarction heart failure

AU - Pitt, Bertram

AU - Ferrari, Roberto

AU - Gheorghiade, Mihai

AU - van Veldhuisen, Dirk J.

AU - Krum, Henry

AU - McMurray, John

AU - Lopez-Sendon, Jose

N1 - 0 Review J

PY - 2006/10

Y1 - 2006/10

N2 - Development of heart failure (HF) or left ventricular systolic dysfunction (LVSD) significantly increases mortality post acute myocardial infarction (AMI). Aldosterone contributes to the development and progression of HF post AMI, and major guidelines now recommend aldosterone blockade in this setting. However, lack of practical experience with aldosterone blockade may make clinicians hesitant to use these therapies. This review is based on a consensus cardiology conference that occurred in May 2005 (New York City) concerning these topics. Potential barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in-hospital pharmacologic management of AMI with LVSD and/or HF is presented.

AB - Development of heart failure (HF) or left ventricular systolic dysfunction (LVSD) significantly increases mortality post acute myocardial infarction (AMI). Aldosterone contributes to the development and progression of HF post AMI, and major guidelines now recommend aldosterone blockade in this setting. However, lack of practical experience with aldosterone blockade may make clinicians hesitant to use these therapies. This review is based on a consensus cardiology conference that occurred in May 2005 (New York City) concerning these topics. Potential barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in-hospital pharmacologic management of AMI with LVSD and/or HF is presented.

KW - aldosterone

KW - myocardial infarction

KW - heart failure

KW - left ventricular systolic dysfunction

KW - eplerenone

KW - EPHESUS

KW - LEFT-VENTRICULAR DYSFUNCTION

KW - SYSTOLIC DYSFUNCTION

KW - RECEPTOR BLOCKADE

KW - ANGIOTENSIN-II

KW - EPLERENONE

KW - ADULT

KW - RAT

KW - SPIRONOLACTONE

KW - MANAGEMENT

KW - MORTALITY

M3 - Review article

SN - 0160-9289

VL - 29

SP - 434

EP - 438

JO - Clinical Cardiology

JF - Clinical Cardiology

IS - 10

ER -

Aldosterone blockade in post-acute myocardial infarction heart failure

Abstract

Keywords

Handle.net

Fingerprint

Cite this